IDEXX Laboratories to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference.

IDEXX Laboratories will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. Jay Mazelsky, President and CEO, and Andrew Emerson, Executive Vice President and CFO, will engage in a fireside chat. A live audio webcast will be available on the IDEXX website. IDEXX is a global leader in pet healthcare innovation, providing diagnostic and software products and services to support veterinarians and advance medical care.

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a leading innovator in pet healthcare, has announced that Jay Mazelsky, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, from 1:50 pm to 2:25 pm (ET). The event will provide investors and industry stakeholders with the opportunity to engage with top executives from IDEXX Laboratories.

The live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will also be accessible via the same link. This event is part of IDEXX Laboratories' ongoing commitment to transparency and investor communication.

IDEXX Laboratories, headquartered in Maine, is a global leader in pet healthcare innovation. With a focus on diagnostic and software products and services, the company supports longer, fuller lives for pets by delivering insights and solutions to the veterinary community worldwide. IDEXX Laboratories employs approximately 11,000 people and offers solutions to customers in more than 175 countries and territories. The company is a member of the S&P 500® Index [1].

The fireside chat will offer insights into IDEXX Laboratories' strategic vision, financial performance, and innovations in pet healthcare. This event follows recent positive financial performance, with the company reporting a revenue growth rate of 10.55% over the three months ending June 30, 2025 [3]. Additionally, IDEXX Laboratories maintains a high gross margin of 62.62%, reflecting strong cost management and profitability [3].

Investors are encouraged to tune in to the live webcast or access the archived presentation for a comprehensive overview of IDEXX Laboratories' latest developments and future prospects.

References:
[1] https://www.marketscreener.com/news/idexx-laboratories-to-participate-in-morgan-stanley-23rd-annual-global-healthcare-conference-ce7d59dad98bf620
[2] https://www.streetinsider.com/Business+Wire/IDEXX+Laboratories+to+Participate+in+Morgan+Stanley+23rd+Annual+Global+Healthcare+Conference/25283775.html
[3] https://www.benzinga.com/insights/news/25/08/47361109/options-exercise-m-anne-szostak-at-idexx-laboratories-realizes-951k